Landos Biopharma, Inc. Common Stock
LABP
LABP was delisted on the 23rd of May, 2024.
34 hedge funds and large institutions have $16.4M invested in Landos Biopharma, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 14 reducing their positions, and 17 closing their positions.
3.6% less ownership
Funds ownership: 59.41% → 55.81% (-3.6%)
24% less funds holding
Funds holding: 45 → 34 (-11)
50% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 14
54% less capital invested
Capital invested by funds: $35.3M → $16.4M (-$18.9M)
59% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 17
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$43.9K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$35.7K |
| 3 |
Goldman Sachs
New York
|
+$21.2K |
| 4 |
E
Ergoteles
New York
|
+$20.8K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$19.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$418K |
| 2 |
JP Morgan Chase
New York
|
-$264K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$234K |
| 4 |
OMC
OUP Management Company
Bala Cynwyd,
Pennsylvania
|
-$195K |
| 5 |
BlackRock
New York
|
-$187K |
LABP Hedge Fund Activity: Q2 2022 in Review
34 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Landos Biopharma, Inc. Common Stock (LABP) for Q2 2022, worth a combined $16.4M — down 54% from $35.3M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of LABP and 7 opened new positions — a net loss of 10 holders — while 14 trimmed existing stakes and 7 added.
The largest buyer was Renaissance Technologies, adding an estimated $43.9K. The largest seller was OrbiMed, exiting entirely with an estimated $418K sold.
- 34 institutional investors held Landos Biopharma, Inc. Common Stock (LABP) as of Q2 2022, down from 45 in Q1 2022.
- Funds reported $16.4M of Landos Biopharma, Inc. Common Stock stock for Q2 2022, down 54% quarter-over-quarter.
- 7 funds opened new Landos Biopharma, Inc. Common Stock positions in Q2 2022 and 17 closed out, a net change of -10 holders.
- The largest Landos Biopharma, Inc. Common Stock buyer in Q2 2022 was Renaissance Technologies, an estimated $43.9K added.
- The largest Landos Biopharma, Inc. Common Stock seller in Q2 2022 was OrbiMed, an estimated $418K sold.
Based on aggregated 13F filings for Q2 2022.